A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Hidradenitis SuppurativaAtopic Dermatitis

Interventions

DRUG

Lutikizumab

Subcutaneous (SC) Injection

Trial Locations (2)

RECRUITING

University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor

RECRUITING

Physioseq, LLC /ID# 267266, Sacramento